Erratum to: Cytomegalovirus disease in adult marrow transplant recipients receiving ganciclovir prophylaxis: a retrospective study (Bone Marrow Transplantation, (1999), 24, 6, (665-669), 10.1038/sj.bmt.1701948);Cytomegalovirus disease in adult marrow transplant recipients receiving ganciclovir prophylaxis: A retrospective study

Bone Marrow Transplantation

Volumn 24, Issue 6, 1999, Pages 665-669

  Maltazou, H ^a   Whimbey, E ^a   Abi Said, D ^a   Przepiorka, D ^a   Champlain, R ^a   Goodrich, J M ^b  

^a UNIVERSITY OF TEXAS   (United States)

^b SOUTHERN ILLINOIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Allogeneic marrow transplant; Cytomegalovirus; FK506; Ganciclovir; T cell depletion; Tacrolimus

Indexed keywords

GANCICLOVIR; TACROLIMUS;

ADOLESCENT; ADULT; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; CYTOMEGALOVIRUS INFECTION; FEMALE; GRAFT VERSUS HOST REACTION; HUMAN; HUMAN CELL; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIVARIATE ANALYSIS; NEUTROPENIA; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR;

EID: 0032829645     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/sj.bmt.1702240     Document Type: Erratum

References (32)

1. Keay S, Petersen E, Icenogle T et al. Ganciclovir treatment of serious cytomegalovirus infection in heart and heart-lung transplant recipients. Rev Infect Dis 1988; 10 (Suppl. 3): s563-s572.
2. Messner HA, Fauser AA. Culture studies of human pluripotent hematopoietic progenitors. Blut 1980; 41: 327-333.
3. Collier AC, Corey L. Therapy of cytomegalovirus infections with ganciclovir: a critical appraisal. Curr Clin Top Infect Dis 1992; 12: 309-328.
4. Laske A, Gallino A, Carrel T et al. Cytomegalovirus infection and prophylaxis in heart transplantation. Transplant Proc 1993; 25: 1427-1428.
5. Egan JJ, Lomax J, Barber L et al. Preemptive treatment for the prevention of cytomegalovirus disease: in lung and heart transplant recipients. Transplantation 1998; 65: 747-752.
6. Wreghitt T. Cytomegalovirus infections in heart and heart-lung transplant recipients. J Antimicrob Chemother 1989; 23 (Suppl. E): 49-60.
7. Kaplan CS, Petersen EA, Icenogle TB et al. Gastrointestinal cytomegalovirus infection in heart and heart-lung transplant recipients. Arch Int Med 1989; 149: 2095-2100.
8. Calhoon JH, Nichols L, Davis R et al. Single lung transplantation. Factors in postoperative cytomegalovirus infection. J Thor Cardiovas Surg 1992; 103: 21-25.
9. Kanj SS, Sharara AI, Clavien PA, Hamilton JD. Cytomegalovirus infection following liver transplantation: review of the literature. Clin Infect Dis 1996; 22: 537-549.
10. Crumpacker CS. Ganciclovir. New Engl J Med 1996; 335: 721-729.
11. Hibberd PL, Tolkoff-Rubin NE, Conti D et al. Preemptive ganciclovir therapy to prevent cytomegalovirus disease in cytomegalovirus antibody-positive renal transplant recipients: a randomized controlled trial. Ann Int Med 1995; 123: 18-26.
12. Boeckh M, Bowden R. Cytomegalovirus infection in marrow transplantation. In: Buckner CD, Clift RA (eds). Technical and Biological Components of Marrow Transplantation. Kluwer Academic Publishers: Boston, 1995, pp 97-136.
13. Goodrich JM, Boeckh M, Bowden R. Strategies for the prevention of cytomegalovirus disease after marrow transplantation. Clin Infect Dis 1994; 19: 287-298.
14. Schmidt GM, Horak DA, Niland JC et al. A randomized, controlled trial of prophylactic ganciclovir for cytomegalovirus pulmonary infection in recipients of allogeneic bone marrow transplants. New Engl J Med 1991; 324: 1005-1011.
15. Goodrich J, Mori M, Cleaves C et al. Early treatment with ganciclovir to prevent cytomegalovirus disease after allogeneic marrow transplant. New Engl J Med 1991; 325: 1601-1607.
16. Goodrich JM, Bowden R, Kellar C, Meyers JD. Prevention of cytomegalovirus disease after allogeneic marrow transplant by ganciclovir prophylaxis. Ann Int Med 1993; 117: 173-178.
17. Winston DJ, Ho WG, Bartoni K et al. Ganciclovir prophylaxis of cytomegalovirus infection and disease in allogeneic marrow transplants. Ann Int Med 1993; 117: 179-184.
18. Boeckh M, Gooley TA, Myerson D et al. Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: a randomized double-blind study. Blood 1997; 88: 4063-4071.
19. Przepiorka D, Ippoliti C, Panina A et al. Ganciclovir three times per week is not adequate to prevent cytomegalovirus reactivation after T-cell depleted marrow transplantation. Bone Marrow Transplant 1994; 13: 461-464.
20. Przepiorka D, Weisdorf D, Martin P et al. 1994 consensus conference on acute GVHD grading. Bone Marrow Transplant 1995; 15: 825-828.
21. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
22. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Res 1966; 50: 163-170.
23. Cox DR. Regression models and life-tables. J R Stat Soc [B] 1972; 34: 187-220.
24. Atkinson K, Downs K, Golenia M et al. Prophylactic use of ganciclovir in allogeneic bone marrow transplantation: absence of clinical cytomegalovirus infection. Br J Haematol 1991; 79: 57-62.
25. Yau JC, Dimopoulos MA, Huan SD et al. Prophylaxis of cytomegalovirus infection with ganciclovir in allogeneic marrow transplantation. Eur J Haematol 1991; 47: 371-376.
26. von Bueltzingsloewen A, Bordigoni P, Witz F et al. Prophylactic use of ganciclovir for allogeneic bone marrow transplant recipients. Bone Marrow Transplant 1993; 12: 197-202.
27. Bunjes D, Hertenstein B, Wiesneth M et al. In vivo/ex vivo T cell depletion reduces the morbidity and mortality of allogeneic bone marrow transplantation in patients with acute leukemia in first remission without increasing the risk of treatment failure: comparison with cyclosporin/methotrexate. Bone Marrow Transplant 1995; 15: 563-568.
28. Enright H, Haake R, Weisdorf D et al. Cytomegalovirus pneumonia after bone marrow transplantation. Transplantation 1993; 55: 1339-1346.
29. Liu J, Farmer JD, Lane WS et al. Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes. Cell 1991; 66: 807-815.
30. Paul AA, Leeper HF, Friberg TR. CMV retinitis and the use of FK 506. Transplant Proc 1991; 23: 3042-3043.
31. Cox KL, Lawrence-Miyasaki S, Garcia-Kennedy R et al. An increased incidence of Epstein-Barr virus infection and lymphoproliferative disorder in young children on FK 506 after liver transplantation. Transplantation 1995; 59: 524-529.
32. Singh N, Gayowski T, Wegner M, Yu VL. Infectious complications of liver transplant recipients on tacrolimus. Transplantation 1994; 58: 774-778.